Cue Biopharma announced that it will present new preclinical data for its lead autoimmune candidate, CUE‑401, at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2026, in Boston. The presentation is scheduled for Saturday, April 18 at 11:30 a.m. EDT in Exhibit Hall and will be led by Director Natasha M. Girgis, who will discuss in‑vivo data supporting CUE‑401’s ability to induce FOXP3+ antigen‑specific regulatory T cells through a bifunctional TGF‑β/IL‑2 fusion protein.
CUE‑401 is designed to restore immune tolerance by delivering coordinated TGF‑β and IL‑2 signals that promote the expansion of regulatory T cells and the conversion of conventional CD4+ T cells into induced Tregs. The data presented at IMMUNOLOGY2026 aim to demonstrate the platform’s potential to treat autoimmune and inflammatory diseases, marking a key scientific milestone for the company’s autoimmune pipeline.
The presentation follows Cue Biopharma’s strategic shift away from oncology, after licensing its most advanced oncology assets. By focusing on autoimmune development, the company seeks to attract partnership interest and additional funding. The new preclinical findings are therefore a critical step toward advancing CUE‑401 toward clinical testing and a potential Phase 1 launch.
In addition to the scientific advance, Cue Biopharma received a $7.5 million preclinical milestone payment from Boehringer Ingelheim on April 8 2026 for its other autoimmune candidate, CUE‑501. The payment underscores the company’s ability to secure external funding and validates its platform technology in the eyes of a major pharmaceutical partner.
For investors monitoring Cue Biopharma’s progress, the IMMUNOLOGY2026 presentation represents a significant event. Positive preclinical data can enhance the company’s attractiveness to potential collaborators and investors, supporting the company’s long‑term growth prospects in the autoimmune space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.